| NCT05232071 | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | 2022-06-29 | 2024-06-04 | 2024-03-30 |
| NCT04849728 | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | RECRUITING | PHASE3 | 2021-08-19 | 2026-09-30 | 2025-09-30 |
| NCT03866369 | Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose | COMPLETED | PHASE1 | 2019-01-17 | 2019-08-27 | 2019-08-27 |
| NCT03370653 | A Study in MPS VI to Assess Safety and Efficacy of Odiparcil | COMPLETED | PHASE2 | 2017-12-30 | 2019-10-22 | 2019-09-24 |
| NCT03008070 | Phase 2b Study in NASH to Assess IVA337 | COMPLETED | PHASE2 | 2017-02-07 | 2020-03-16 | 2020-02-20 |
| NCT02503644 | Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis | COMPLETED | PHASE2 | 2015-10-29 | 2018-10-12 | 2018-10 |